Sign Up
Ready to replace complexity with clarity?
Answer your real world compliance questions (limited time) and save thousands in legal fees and avoided fines.
Automate Compliance TodayUS states A to Z: marijuana, THCA, delta-8, delta-9, delta-10, HHC
State-by-state mapMost read countries: marijuana, CBD and hemp status
All countries on the globeSubstances: status in every state for each one
Compare all substancesFederal hemp redefinition: P.L. 119-103, div. B, sec. 2019
Nov 12, 2026
Applies only to cannabinoids the plant cannot naturally produce.
Dec 11, 2026
The total-THC test, the 0.4 mg per container cap and the exclusion of converted cannabinoids start.
Latest regulatory actions, updated daily
All regulatory actionsHeadlines and the first four sentences are free. Full write-ups, impact reasoning and the archive are for members.
Member · $99/mo
Every rule change, the day it is made.
The price will rise. Join now and $99 a month stays your rate for life.
Become a memberOr read free: every action opens 30 days after it is published. Sign in with email
By topic
Licensing and permitsPackaging and labelingLab testing and QARetail complianceAdvertising and marketingBanking and paymentsTaxesShipping and logisticsTravel and transportLitigationSOPsFor your role
Regulators and agenciesBrands and operatorsRetailers and smoke shopsCultivatorsProcessorsLawyers and complianceInvestorsConsumers and travelersThe Regulator Brief · newsletter
Every rule change that matters, every Monday.
Free: the Monday brief, and every action 30 days after it is published.
Members: the paid weekly, daily alerts and every write-up.
Read by regulators, operators, lawyers and founders.
Cannabis lawyers
Licensed by state. Listings are not endorsements.
By state
Software and services
Compared by fit, never ranked.
Categories
For companies and firms
Be the listing operators and regulators find.
Software and services
Verified, $49/mo: domain-verified badge, your website link, a quote.
Featured, from $399/mo: labeled Featured in your category, monthly release notes.
Lawyers and firms
Claimed, $75/yr: Claimed badge and your firm's website link.
Featured, $199/mo: labeled Featured on your profile.
Claim your companyClaim a lawyer listingPlacements, flat monthly fee
State and country page sponsorshipsExclusive slot on a legality page and its postsRegulator Brief sponsorshipPresenting sponsor or mid-issue banner, free editionMember brief sponsor slotThe paid weekly, read by members onlyFeatured directory placementLabeled Featured in a software categoryCategory sponsorshipOwn one directory category across the sitePaid guest postsLabeled Paid guest post, sponsored linksWrite and partner
Pitch a paid guest postRead guest postsBecome an affiliateSend a tip or correctionContact the teamWho reads it
Regulators at federal, state and county agencies, plus the operators, lawyers and founders they regulate.
Get the media kitSee open placementsSubstances
US states, map and A to ZCountriesFederal hemp 2026: Nov 12 and Dec 11Compound index, every stateTravelling with cannabis or hempMembers get the daily alert email and every full write-up the morning it is published. Every action is free to read 30 days later.
For your role
All news and analysisGuidesAnalysisFAQsTemplates and SOPsCourt filing recapsNews by state and countrySoftware and services: Verified $49/mo, Featured from $399/mo. Lawyers and firms: Claimed $75/yr, Featured $199/mo. Listings are not endorsements.
Regulatory journalism, not legal advice. How we report

The National Advertising Division (NAD) of BBB National Programs has maintained its assertive oversight in 2025, particularly for health and functional product advertising—including the emerging CBD and hemp-derived beverage sector. With the FDA and FTC both ramping up enforcement against unsubstantiated health claims, the standards applied in traditional supplement and functional food cases are informing what is now expected for CBD, CBG, and other cannabinoid-infused beverages. For brands planning Q4 launches in 2025, understanding NAD’s most recent activity, substantiation requirements, and coordination with federal agencies is critical for cannabis compliance and risk management.
NAD’s 2025 case summaries and conference commentary highlight active monitoring of sleep, pain, stress, recovery, and wellness benefit claims. While CBD and cannabinoids remain under close scrutiny by the FDA and FTC, NAD’s self-regulatory process continues to influence market guardrails, regardless of formal FDA approval for ingestible CBD products.
NAD decisions in 2025 for dietary supplements, nootropics, and adaptogenic beverages directly inform what’s likely defensible in the cannabinoid space. Key issue areas from these cases include:
The NAD expects CBD beverage brands to support their claims with human clinical evidence when asserting health or performance benefit statements. In-vitro, animal, or mechanistic data can supplement—but not replace—the need for well-controlled, peer-reviewed human studies.
NAD’s 2025 reviews continue to reiterate that disclaimers (like “results may vary” or “not evaluated by the FDA”) do not shield marketers from responsibility. Brands cannot make substantive health promises and then attempt to disclaim them in footnotes. Structure–function claims—such as “supports relaxation” or “promotes restful sleep”—must still be supported by real human evidence and be wording-appropriate for the studied data.
Parallel to NAD’s activity, the FTC and FDA have sent an ongoing stream of warning letters to companies making unsubstantiated CBD beverage claims in 2025. Enforcement trends include:
For a recent roundup, CannabisRegulations.ai’s analysis of 2025 warning letters highlights the ongoing crackdown on deceptive health claims and the requirement for full transparency.
For those planning to make health/function claims for CBD or any cannabinoid beverage, the safest route according to NAD doctrine is having:
This gold standard is particularly important for claims around sleep support, stress reduction, and pain relief—areas most targeted by FTC/FDA.
With no formal federal approval for CBD beverages as dietary supplements or food additives in 2025, NAD, FTC, and FDA serve as de facto regulatory gatekeepers. State-level requirements for cannabinoid beverages (age-gating, labeling, and marketing restrictions) are layered on top of these expectations. Brands are urged to implement robust risk assessments, substantiation file documentation, and continuous monitoring of new NAD, FDA, and FTC developments.
For further learning, review NAD case summaries and FDA’s list of recent warning letters targeting CBD and food/beverage marketers.
The NAD’s decisions and federal enforcement posture in 2025 make one thing clear: Only rigorously supported, cautiously worded claims will withstand scrutiny for CBD and hemp-derived beverages. Brands that invest early in science, documentation, and compliance culture can launch with confidence and minimize exposure in the ever-evolving regulatory landscape.
If you are preparing to launch or update a CBD beverage brand, leverage CannabisRegulations.ai for real-time guidance and best practices in cannabis compliance, marketing substantiation, and state/federal regulatory tracking.